NCT01309789 2017-06-28A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell NeoplasmsSeagen Inc.Phase 1 Completed39 enrolled